Comparing efficacy of oral immunosuppressants in patients with moderate to severe psoriasis
- Conditions
- Health Condition 1: L409- Psoriasis, unspecified
- Registration Number
- CTRI/2024/05/068034
- Lead Sponsor
- Surbhi Jain Self
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Clinically diagnosed patients with moderate to severe psoriasis
2. Patients aged 18 - 60 years
3. PASI score of = 5 or Body surface area involvement of = 10%
4. Patients providing informed consent
1. Patients with uncontrolled or major forms of psoriasis which are life threatening
2. Patients on active topical agents
3. Patients taking other systemic drugs for psoriasis in last 2 months
4. Patient taking other drugs which can interfere with Methotrexate or Apremilast or Cyclosporine
5. Patients on biologics within the past 2 weeks
6. Patients with liver or renal impairment or anaemia or thrombocytopenia or leukopenia
7. Patients with hepatitis B, C, HIV or TB infection
8. Patients with a co-existing comorbidity like diabetes mellitus, uncontrolled hypertension and psychiatric illness
9. Pregnant and breastfeeding patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method